Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy: Critical Reviews in Oncology/Hematology

S. Arcangeli, B.A. Jereczek-Fossa, F. Alongi, C. Aristei, C. Becherini, L. Belgioia, M. Buglione, L. Caravatta, R.M. D'Angelillo, A.R. Filippi, M. Fiore, D. Genovesi, C. Greco, L. Livi, S.M. Magrini, G. Marvaso, R. Mazzola, I. Meattini, A. Merlotti, I. PalumboS. Pergolizzi, S. Ramella, U. Ricardi, E. Russi, M. Trovò, A. Sindoni, V. Valentini, R. Corvò

Research output: Contribution to journalArticle


Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy. © 2018 Elsevier B.V.
Original languageEnglish
Pages (from-to)87-103
Number of pages17
JournalCrit. Rev. Oncol. Hematol.
Publication statusPublished - 2019



  • abiraterone
  • anastrozole
  • antineoplastic agent
  • apalutamide
  • bevacizumab
  • capecitabine
  • cetuximab
  • cisplatin
  • docetaxel
  • enzalutamide
  • erlotinib
  • everolimus
  • exemestane
  • gemcitabine
  • imatinib
  • letrozole
  • nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor
  • oxaliplatin
  • paclitaxel
  • panitumumab
  • pertuzumab
  • sonidegib
  • sorafenib
  • sunitinib
  • temozolomide
  • trastuzumab
  • unindexed drug
  • veliparib
  • vemurafenib
  • vismodegib
  • radiosensitizing agent
  • basal cell carcinoma
  • brain metastasis
  • breast cancer
  • cancer combination chemotherapy
  • cancer control
  • cancer radiotherapy
  • cancer survival
  • carcinomatous peritonitis
  • clinical effectiveness
  • digestive system cancer
  • drug efficacy
  • drug safety
  • esophageal adenocarcinoma
  • gastrointestinal stromal tumor
  • glioblastoma
  • glioma
  • head and neck squamous cell carcinoma
  • human
  • human epidermal growth factor receptor 2 negative breast cancer
  • human epidermal growth factor receptor 2 positive breast cancer
  • kidney cancer
  • kidney metastasis
  • melanoma
  • metastatic breast cancer
  • metastatic colorectal cancer
  • muscle invasive bladder cancer
  • non small cell lung cancer
  • nonhuman
  • pancreas cancer
  • pancreas islet cell tumor
  • phase 2 clinical trial (topic)
  • phase 3 clinical trial (topic)
  • prostate cancer
  • rectum cancer
  • renal cell carcinoma
  • Review
  • solid malignant neoplasm
  • treatment failure
  • chemoradiotherapy
  • Italy
  • neoplasm
  • treatment outcome
  • Chemoradiotherapy
  • Humans
  • Neoplasms
  • Radiation-Sensitizing Agents
  • Treatment Outcome

Cite this